Loading organizations...
Loading organizations...
Earlens is a technology company.
Earlens is a medical technology company developing a unique hearing solution that directly stimulates the eardrum. Its core product, a novel hearing aid system, utilizes a small lens placed on the eardrum, connected to an external processor, to deliver sound through direct vibration rather than air conduction. This approach aims to provide a broader frequency range and more natural sound experience for individuals with hearing impairment.
The company was founded by Dr. Rodney Perkins, a distinguished physician, entrepreneur, and Professor of Surgery at the Stanford School of Medicine. Dr. Perkins' insight stemmed from a deep understanding of auditory mechanics, recognizing the limitations of conventional air-conduction hearing aids and pioneering a method to achieve more comprehensive sound perception by directly engaging the eardrum.
Earlens primarily serves individuals experiencing various forms of hearing loss. The company’s vision is to fundamentally transform the hearing aid landscape by offering a technologically advanced solution that significantly enhances sound quality and user experience. It continues to focus on innovating within auditory assistance, moving towards a future where hearing impairment can be addressed with greater fidelity.
Earlens has raised $281.0M across 4 funding rounds.
Earlens has raised $281.0M in total across 4 funding rounds.
Earlens has raised $281.0M in total across 4 funding rounds.
Earlens's investors include Aisling Capital, Morgenthaler Ventures, Vertex Ventures HC, Cochlear, Luke Duster, Lightstone Ventures, Medtronic, New Enterprise Associates, RK Mellon, Sightline Partners, Windham Venture Partners.
Earlens is a medical technology company developing an innovative hearing aid solution that directly vibrates the eardrum for superior sound quality.[1][9] It builds a custom-fit system comprising a behind-the-ear Processor, a flexible Ear Tip, and a tiny Lens placed on the eardrum by an ENT physician, serving adults with mild to severe hearing loss who struggle with traditional hearing aids in noisy environments.[1][2][3] The product solves key limitations of conventional speaker-based hearing aids—such as distortion, whistling (feedback), limited frequency range (typically up to 5 kHz), and poor speech understanding in noise—by using radio signals to transmit audio data inductively, enabling a 2.5x broader bandwidth (up to ~10 kHz) for natural, high-fidelity sound.[2][3][5][7] Growth momentum includes over 180 patents, FDA approvals for iterative technologies (light-based in 2015, radio-frequency in 2019), and recognition as one of TIME's Top 100 Inventions in 2020, with custom manufacturing in Silicon Valley and distribution through select ENT-audiologist partnerships.[3][4]
Earlens was founded in 2005 by Dr. Rodney Perkins, an otologist (ear surgeon) and inventor leveraging his medical expertise to rethink hearing restoration.[3] The idea emerged from Perkins' recognition that traditional hearing aids' speaker amplification distorted sound and failed in noise; he pioneered a "lens-driven" approach to bypass the ear canal and directly activate the body's natural hearing via eardrum vibration.[2][3] Early traction came from a first-generation infrared laser system (FDA-patented 2015), which faced alignment issues leading to a more reliable second-generation radio-frequency inductive method (patented 2019).[3] Pivotal moments include accumulating 180+ patents, clinical studies showing vast majority of users preferred it for noisy/group settings, and 2020 TIME acclaim, solidifying its shift from prototype to commercial rollout.[3][2]
Earlens stands out in the hearing aid market through its unique direct-drive mechanism and patient-centric design:
Earlens rides the wave of contact hearing innovation and medtech convergence with consumer electronics, addressing a $7B+ global hearing aid market where 80% of users report dissatisfaction with sound in noise.[2][3] Timing aligns with aging populations (1 in 3 over 65 have hearing loss) and post-pandemic demand for clear communication, amplified by wireless tech advances like reliable RF transmission.[3][4] Favorable forces include regulatory wins (FDA nods), patent moats (180+), and clinician endorsements likening it to "filet mignon vs. hotdog," positioning it as a premium disruptor.[1][3] It influences the ecosystem by elevating standards—pushing rivals toward wider bandwidths—and fostering ENT-audiologist collaborations, while validating Silicon Valley's bio-engineering for sensory tech.[1][8]
Earlens is poised for expansion via broader provider networks, international scaling, and app enhancements for AI-driven personalization amid rising telehealth.[4][6] Trends like high-fidelity audio integration (e.g., Bluetooth LE Audio) and longevity-focused medtech will propel it, potentially capturing share from stagnant traditional aids as awareness grows.[3][9] Its influence may evolve toward fully implantable variants or ecosystem plays with wearables, redefining hearing as immersive rather than amplified—cementing its role as the premium choice for transformative sound.[1][2]
Earlens has raised $281.0M across 4 funding rounds. Most recently, it raised $25.0M Other Equity in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 15, 2021 | $25.0M Other Equity | ||
| Oct 1, 2018 | $87.0M Series D | Aisling Capital, Morgenthaler Ventures | |
| Jun 5, 2017 | $118.0M Debt / Series C | Vertex Ventures HC | Aisling Capital, Cochlear, Luke Duster, Lightstone Ventures, Medtronic, New Enterprise Associates, RK Mellon, Sightline Partners, Windham Venture Partners |
| Jun 27, 2016 | $51.0M Other Equity / Series C | Vertex Ventures HC | Aisling Capital, Cochlear, Lightstone Ventures, Medtronic, New Enterprise Associates |